Articles by Laurence Albiges, MD, PhD
The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.
The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.
The panel explains how the approval of subcutaneous nivo offers advantages in patient convenience and healthcare efficiency.
The panel weighs long-term treatment-free survival with nivo/ipi against the need for disease control with IO-TKI combos.
The panel considers the limitations of ctDNA from low tumor shedding but expresses optimism for detection technology.
The panel weighs the evolving role of biomarkers, particularly the promising blood-based biomarker KIM-1.
Dr. Albiges details the final results of COSMIC-313, highlighting the effectiveness of cabo plus nivo/ipi for aRCC.
Dr. Albiges discusses the logistical benefits and considerations of subcutaneous administration of nivolumab for RCC.
Dr. Albiges summarizes the CheckMate 67T study, which evaluated the safety and efficacy of subcutaneous nivolumab for RCC.
In part 3 of the session, the panel discusses the latest developments in treatments for papillary kidney cancer.
In the second part of the session, the panel highlights some of the most important recent developments in papillary RCC.
In part one of the session, the panelists dive into an in-depth exploration and debate on the results of SUNNIFORECAST.
In the final part of this roundtable series, the panelists share their thoughts on the most anticipated upcoming trials.
In the fifth segment of this roundtable, the panelists discuss the challenges and barriers of ipi-nivo therapy.
The fourth segment of this roundtable series focuses on the potential benefits of subcutaneous nivolumab versus IV nivolumab.
The third segment of this roundtable focuses on key treatment endpoints when deciding between IO-IO and IO-TKI regimens.
The panel delves into the utility of sarcomatoid features, PD-L1 status, and emerging biomarkers like KIM 1 and ctDNA.
An expert panel debates the latest strategies for optimizing first-line treatment for advanced renal cell carcinoma.
In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.
In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.